UPB UPSTREAM BIO INC

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET.

A live webcast of the fireside chat will be available under the tab on the Investors section of the Company’s website. A replay will be posted on the Company's website following the presentation.

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit .

Investor and Media Contact:

Meggan Buckwell

Director, Corporate Communications and Investor Relations



EN
09/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UPSTREAM BIO INC

 PRESS RELEASE

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio to Participate in Upcoming November Investor Conferences WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium, New York, NYThursday, November 6, 2025, Panel - 8:10 a.m. ETStifel 2025 Healthcare Conference, New York, NYTuesday, Nove...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

BKD BROOKDALE SENIOR LIVING INC.
XENE XENON PHARMACEUTICALS INC
SEDG SOLAREDGE TECHNOLOGIES INC.
RUN SUNRUN INC.
LTRX LANTRONIX INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LAKE LAKELAND INDUSTRIES INC.
CEVA CEVA INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ALB ALBEMARLE CORPORATION
EFR ENERGY FUELS
RELL RICHARDSON ELECTRONICS LTD.
NTLA INTELLIA THERAPEUTICS INC.
UAMY UNITED STATES ANTIMONY CORP.
BOMN BOSTON OMAHA
ICL ICL GROUP LTD.
LWLG LIGHTWAVE LOGIC
IMTX IMMATICS N V (A)
ARRY ARRAY TECHNOLOGIES
IMVT IMMUNOVANT
RLAY RELAY THERAPEUTICS
FLUX FLUX POWER HOLDINGS
GLUE MONTE ROSA THERAPEUTICS INC
ASTS AST SPACEMOBILE INC
TRDA ENTRADA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
APLD APPLIED BLOCKCHAIN INC
IE IVANHOE ELECTRIC INC
NUVL NUVALENT INC
COHR COHERENT CORP
CRML CLAL INDUSTRIES & BEVERAGES LTD
GPCR STRUCTURE THERAPEUTICS
OCS OCULIS HOLDING AG
LAES SEALSQ CORP
NB NIOCORP DEVELOPMENTS LTD.
METBV FORTREA HOLDINGS INC.
FTREV SAGIMET BIOSCIENCES INC
SGMT BYRNA TECHNOLOGIES INC
BYRN ENGENE HOLDINGS INC
ENGN SPYRE THERAPEUTICS INC.
SYRE NEUROGENE INC
NGNE RAMACO RESOURCES INC.
METC TOYO CO LTD
TOYO SERVE ROBOTICS INC
SERV UPSTREAM BIO INC
UPB CIDARA THERAPEUTICS INC.
CDTX AMERICAN BATTERY TECHNOLOGY COMPANY
ABAT TVARDI THERAPEUTICS INC
TVRD USA RARE EARTH INC
USAR HYCROFT MINING HOLDING CORPORATION
HYMC CATALYST PERINI STRATEGIC INCOM ORD
CSIOX CHARGEPOINT HOLDINGS INC.
CHPT KULR TECHNOLOGY GROUP INC.
KULR GRAFTECH INTERNATIONAL LTD.
EAF GLOBALSTAR INC.
GSAT INHIBRX BIOSCIENCES INC.
INBX KON TUM CONSTRUCTION MATERIALS ORD
 PRESS RELEASE

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers ...

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress – Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug’s unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respirato...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and ...

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET. A live webcast of the fireside chat will be available under the tab on...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch